A Study of LY3435151 in Participants With Solid Tumours

Official Title

A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumours


The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumours.

Trial Description

Primary Outcome:

  • Number of Participants with LY3435151 Dose-Limiting Toxicities (DLTs)
Secondary Outcome:
  • Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3435151
  • PK: Cmax of LY3435151 in Combination with Pembrolizumab
  • Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR)
  • Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of CR, PR, and Stable Disease
  • Duration of Response (DoR)
  • Time to Response (TTR)
  • Progression Free Survival (PFS)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society